For pre-invasive disease:
the prevalence of HPV infection at 18 years was 10%;
the prevalence of low-grade SIL at 18 years was 1%;
the age-specific incidence of HPV infection ranged from 0.17 at 19 years to 0.005 at 50 years and older;
the age-specific regression rate of HPV was 0.7/18 months for women aged 15 to 24 years, 0.5/18 months for those aged 25 to 29, and 0.15/18 months for those aged 30 and older;
the progression rate from HPV to low-grade SIL was 0.2/36 months;
the proportion of infections progressively directed to high-grade SILs was 0.1;
the regression rate from low-grade SILs to HPV or well was 0.65/72 months for women aged 15 to 34 years and 0.4/72 months for women older than 34 years;
the proportion of low-grade SILs reverting to well was 0.9;
the progression rate from low- to high-grade SILs was 0.1/72 months for women aged 15 to 34 years and 0.35/72 months for women older than 34 years;
the regression rate from high- to low-grade SILs was 0.35/72 months;
the proportion of high-grade SILs reverting to well was 0.5; and
the progression rate from high-grade SILs to stage I cancer was 0.4/120 months.
For invasive disease:
the progression rates in unscreened patients with cancer were 0.9/4 years for stage I-stage II, 0.9/3 years for stage II-stage III, and 0.9/2 years for stage III-stage IV;
5-year survival was 0.83 in stage I, 0.6566 in stage II, 0.3787 in stage III, and 0.1127 in stage IV.